Corrigendum to: “Preventive and therapeutic effects of caffeic acid against inflammatory injury in striatum of MPTP-treated mice”: [Eur.J.Pharmacol.670(2011)441-447] (S001429991101154X) (10.1016/j.ejphar.2011.09.171));Preventive and therapeutic effects of caffeic acid against inflammatory injury in striatum of MPTP-treated mice

European Journal of Pharmacology

Volumn 670, Issue 2-3, 2011, Pages 441-447

  Tsai, Shih Jei ^a,b   Chao, Che Yi ^c   Yin, Mei Chin ^c,d  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c ASIA UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Caffeic acid; Cytokine; Neurotrophin; NOS activity; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ADAPTOR PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CAFFEIC ACID; CYCLOOXYGENASE 2; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; IONIZED CALCIUM BINDING ADAPTOR MOLECULE 1; MESSENGER RNA; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CYTOKINE RELEASE; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; GENE EXPRESSION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; UPREGULATION;

EID: 80755153266     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2017.12.048     Document Type: Erratum

References (33)

1. E. Bezard, S. Dovero, C. Prunier, P. Ravenscroft, S. Chalon, D. Guilloteau, A.R. Crossman, B. Bioulac, J.M. Brotchie, and C.E. Gross Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- lesioned macaque model of Parkinson's disease J. Neurosci. 21 2001 6853 6861 (Pubitemid 32781128)
2. P.C. Chao, C.C. Hsu, and M.C. Yin Anti-inflammatory and anti-coagulatory activities of caffeic acid and ellagic acid in cardiac tissue of diabetic mice Nutr. Metab. (Lond) 6 2009 33
3. J.Y. Choi, C.S. Park, D.J. Kim, M.H. Cho, B.K. Jin, J.E. Pie, and W.G. Chung Prevention of nitric oxide-mediated 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate Neurotoxicology 23 2002 367 374
4. W. Eberhardt, T. Beeg, K.F. Beck, S. Walpen, S. Gauer, H. Böhles, and J. Pfeilschifter Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells Kidney Int. 57 2000 59 69 (Pubitemid 30227754)
5. B. Ferger, A. Leng, A. Mura, B. Hengerer, and J. Feldon Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum J. Neurochem. 89 2004 822 833 (Pubitemid 38684730)
6. U.E. Ghitza, H. Zhai, P. Wu, M. Airavaara, Y. Shaham, and L. Lu Role of BDNF and GDNF in drug reward and relapse: a review Neurosci. Biobehav. Rev. 35 2010 157 171
7. D.B. Hancock, E.R. Martin, J.M. Vance, and W.K. Scott Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease Neurogenetics 9 2008 249 262
8. E.C. Hirsch, and S. Hunot Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 8 2009 382 397
9. E.C. Hirsch, T. Breidert, E. Rousselet, S. Hunot, A. Hartmann, and P.P. Michel The role of glial reaction and inflammation in Parkinson's disease Ann. N. Y. Acad. Sci. 991 2003 214 228 (Pubitemid 36793816)
10. R. Kurosaki, Y. Muramatsu, H. Watanabe, M. Michimata, M. Matsubara, Y. Imai, and T. Araki Role of dopamine transporter against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice Metab. Brain Dis. 18 2003 139 146 (Pubitemid 36718126)
11. C. Levecque, A. Elbaz, J. Clavel, F. Richard, J.S. Vidal, P. Amouyel, C. Tzourio, A. Alpérovitch, and M.C. Chartier-Harlin Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study Hum. Mol. Genet. 12 2003 79 86 (Pubitemid 36104179)
12. Z. Li, D.Y. Choi, E.J. Shin, R.L. Hunter, C.H. Jin, M.B. Wie, M.S. Kim, S.J. Park, G. Bing, and H.C. Kim Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity Neurosci. Lett. 445 2008 1 6
13. A.R. Little, and J.P. O'Callagha Astrogliosis in the adult and developing CNS: is there a role for proinflammatory cytokines? Neurotoxicology 22 2001 607 618 (Pubitemid 33134236)
14. B. Liu, and J.S. Hong Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention J. Pharmacol. Exp. Ther. 304 2003 1 7 (Pubitemid 36008905)
15. J.L. Madrigal, O. Hurtado, M.A. Moro, I. Lizasoain, P. Lorenzo, A. Castrillo, L. Boscá, and J.C. Leza The increase in TNF-alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immnbilization stress Neuropsychopharmacology 26 2002 155 163 (Pubitemid 34093078)
16. M. Mogi, M. Harada, P. Riederer, H. Narabayashi, K. Fujita, and T. Nagatsu Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients Neurosci. Lett. 165 1994 208 210
17. A. Nakashima, N. Hayashi, Y.S. Kaneko, K. Mori, E.L. Sabban, T. Nagatsu, and A. Ota Role of N-terminus of tyrosine hydroxylase in the biosynthesis of catecholamines J. Neural. Transm. 116 2009 1355 1362
18. N.H. Neff, T.A. Wemlinger, A.M. Duchemin, and M. Hadjiconstantinou Clozapine modulates aromatic L-amino acid decarboxylase activity in mouse striatum J. Pharmacol. Exp. Ther. 317 2006 480 487
19. T. Okuno, Y. Nakatsuji, A. Kumanogoh, M. Moriya, H. Ichinose, H. Sumi, H. Fujimura, H. Kikutani, and S. Sakoda Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson's disease J. Neurosci. Res. 81 2005 874 882 (Pubitemid 41532153)
20. J.R. Richardson, W.M. Caudle, M. Wang, E.D. Dean, K.D. Pennell, and G.W. Miller Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease FASEB J. 20 2006 1695 1697
21. C. Rosenbald, D. Kirik, and A. Björklund Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model Exp. Neurol. 161 2000 503 516 (Pubitemid 30137010)
22. R.B. Silverman Design of selective neuronal nitric oxide synthase inhibitors for the prevention and treatment of neurodegenerative diseases Acc. Chem. Res. 42 2009 439 451
23. J. Sochor, O. Zitka, H. Skutkova, D. Pavlik, P. Babula, B. Krska, A. Horna, V. Adam, I. Provaznik, and R. Kizek Content of phenolic compounds and antioxidant capacity in fruits of apricot genotypes Molecules 15 2010 6285 6305
24. S. Sugama, T. Takenouchi, B.P. Cho, T.H. Joh, M. Hashimoto, and H. Kitani Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models Inflamm. Allergy Drug Targets 8 2009 277 284
25. T. Sun, P.W. Simon, and S.A. Tanumihardjo Antioxidant phytochemicals and antioxidant capacity of biofortified carrots (Daucus carota L.) of various colors J. Agric. Food Chem. 57 2009 4142 4147
26. B.A. Sutherland, O.M. Shaw, A.N. Clarkson, D.N. Jackson, I.A. Sammut, and I. Appleton Neuroprotective effects of (-)-epigallocatechin gallate following hypoxia-ischemia-induced brain damage: novel mechanisms of action FASEB J. 19 2005 258 260 (Pubitemid 40189274)
27. M.G. Tansey, T.C. Frank-Cannon, M.K. McCoy, J.K. Lee, T.N. Martinez, F.E. McAlpine, K.A. Ruhn, and T.A. Tran Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy? Front. Biosci. 13 2008 709 717 (Pubitemid 351599776)
28. P. Teismann, K. Tieu, D.K. Choi, D.C. Wu, A. Naini, S. Hunot, M. Vila, V. Jackson-Lewis, and S. Przedborski Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration Proc. Natl. Acad. Sci. U. S. A. 100 2003 5473 5478 (Pubitemid 36542729)
29. S.J. Tsai, W.W. Kuo, W.H. Liu, and M.C. Yin Antioxidative and anti-inflammatory protection from carnosine in the striatum of MPTP-treated mice J. Agric. Food Chem. 58 2010 11510 11516
30. D. Vauzour, G. Ravaioli, K. Vafeiadou, A. Rodriguez-Mateos, C. Angeloni, and J.P. Spencer Peroxynitrite induced formation of the neurotoxins 5-S-cysteinyl-dopamine and DHBT-1: implications for Parkinson's disease and protection by polyphenols Arch. Biochem. Biophys. 476 2008 145 151
31. R. Vijitruth, M. Liu, D.Y. Choi, X.V. Nguyen, R.L. Hunter, and G. Bing Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease Neuroinflammation 3 2006 6
32. C. Woiciechowsky, B. Schöning, G. Stoltenburg-Didinger, F. Stockhammer, and H.D. Volk Brain-IL-1 beta triggers astrogliosis through induction of IL-6: inhibition by propranolol and IL-10 Med. Sci. Monit. 10 2004 325 330
33. Y. Yamada, H. Yasui, and H. Sakurai Suppressive effect of caffeic acid and its derivatives on the generation of UVA-induced reactive oxygen species in the skin of hairless mice and pharmacokinetic analysis on organ distribution of caffeic acid in ddY mice Photochem. Photobiol. 82 2006 1668 1676 (Pubitemid 46158862)